Company Analysis

Redhill Biopharma Ltd. RDHL

A comprehensive view of key metrics, scores, and financial health for Redhill Biopharma Ltd.

Overview of RedHill Biopharma Ltd.

RDHL NCM

Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Micro Cap

RedHill Biopharma Ltd. (RDHL), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $0.69, about 0.0% overvalued vs fair value, -53.2% 1Y return, ranked 975/1145 in sector.

Metrics ROE 206.8%

USD 0.69

-1.43%

(Delayed)

• Vol 90d: 79.1%

Market Cap

$3.60M

Enterprise Value

$699,000

Overall Score

View breakdown

Overall

Growth

Fair

Profitability

Weak

Health

Weak

Efficiency

Weak

Valuation

Weak

Growth

Fair

Profitability

Weak

Health

Weak

Efficiency

Weak

Valuation

Weak

Completeness: 82%

Confidence: 85%

Updated: Jul 5

Top Beats

Quick Facts

Website https://www.redhillbio.com

HQ Tel Aviv

Employees 35

Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull

$-2

Current: $0.69

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps

Total Revenue

$286.0K

Gross Profit

$4.9M

58%%

R&D Expense

$2.0M

27.4%%

Operating Income (EBIT)

$-8.1M

-2095.3%%

Money Flow Bridge

You are currently seeing a limited view of the money flow waterfall.

See the full waterfall with all stages on Premium. Upgrade

Flow Direction: Money moves from left to right

Components: Breakdown shows composition of each stage

Industry-Specific: Pharmaceutical / Mature Biotech

Data Quality Notes

Negative operating cash flow is unusual for established pharma. This may indicate a transition period or should be investigated.
Negative free cash flow. Check if this is due to heavy CapEx, acquisitions, or operational challenges.
R&D intensity is 707.3% of revenue, indicating heavy investment in pipeline development.
Patent cliff risk: Monitor expiring exclusivity periods and pipeline readiness. Strong pharma companies have robust pipelines to replace expiring products.

Quality & Reliability Indicators

R&D Intensity

707.3%

Fair

High R&D intensity - heavy pipeline investment

Locked Metric

Premium

Where It Leaks

Cash Flow Health critical

Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.

Active Leaks

0/3

Improving

High Impact

Critical

Non-Cash Earnings Intensity

Current: 293.5%

Conversion Leak

Locked Leak

Upgrade to view details

Premium

Locked Leak

Upgrade to view details

Premium

Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak

Premium

Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.

For informational purposes only. Not investment advice.

Cost Advantage

Weak

Customer Stickiness

Weak

Capital Efficiency

Developing

Resilience

Weak

Scale & Market Position

Weak

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 92% Coverage

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked

Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

36th percentile vs peers

Key Signals

Rev Growth YoY 23.2% 82p EPS Growth YoY -1.07 11p Revenue CAGR 3Y -83.3% 1p

Strengths

Rev Growth YoY in top 20% of peers (23.2%, 82th percentile)
Superior capital returns - 2 return metrics above peer median
Conservative leverage compared to industry peers

Risks

EPS Growth YoY in bottom 20% of peers (-1.07)

Profitability

26th percentile vs peers

Key Signals

Strengths

Risks

Premium

Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

37th percentile vs peers

Key Signals

Strengths

Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Redhill Biopharma Ltd..

WACC X.X%

X%XX%

Rev CAGR 5Y X.X%

-XX%XX%

Op Margin XX.X%

-XX%XX%

Adjust the sliders above to explore different valuation scenarios.

Unlock Premium

Reveal the full Scenario Theatre

See live sliders, narratives, and full Bear/Base/Bull outcomes.

Upgrade Now

Bear

- - -

- upside

Base

$-2.36

- - -

- upside

Snapshot base estimate

Bull

- - -

- upside

Fair Value Range Current: $-

$- $- $-

Redhill Biopharma Ltd. RDHL

Overview of RedHill Biopharma Ltd.

Quick Facts

Next Events

Fair Value Snapshot

Engine Room Money Flow™

Flow Steps

Money Flow Bridge

Data Quality Notes

Quality & Reliability Indicators

R&D Intensity

Locked Metric

Where It Leaks

Non-Cash Earnings Intensity

Thresholds

Key Metrics

Locked Leak

Locked Leak

Competitive Advantage Assessment

Unlock full defense analysis

Pricing Power

Unlock full defense details

Cost Advantage

Unlock full defense details

Customer Stickiness

Unlock full defense details

Capital Efficiency

Unlock full defense details

Resilience

Unlock full defense details

Scale & Market Position

Unlock full defense details

Trade-Off Ledger™

Growth

Profitability

Safety

Two Futures

Actions & Info

Send Feedback